Pipex Pharmaceuticals’ Oral TRIMESTA Phase IIa Clinical and Preclinical Findings Presented at World Congress on Treatment and Research in Multiple Sclerosis Meeting

ANN ARBOR, MI--(Marketwire - September 19, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of autoimmune and central nervous system diseases, announced today that its scientific collaborator has presented new findings from a phase IIa clinical trial results using estriol for the treatment of multiple sclerosis at the World Congress on Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS, ECTRIMS and LACTRIMS) in Montreal, Canada. Estriol is the active ingredient in TRIMESTA.